101 Markers of neurodegeneration in subjective cognitive decline 41. Velickaite V, Ferreira D, Lind L, Ahlström H, Kilander L, Westman E, et al. Visual rating versus volumetry of regional brain atrophy and longitudinal changes over a 5-year period in an elderly population. Brain and behavior. 2020;10(7):e01662. 42. Knoops AJ, van der Graaf Y, Appelman AP, Gerritsen L, Mali WP, Geerlings MI. Visual rating of the hippocampus in non-demented elders: Does it measure hippocampal atrophy or other indices of brain atrophy? The SMART-MR study. Hippocampus. 2009;19(11):1115-22. 43. Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, et al. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology. 2019;93(17):e1635-e46. 44. Burnham SC, Coloma PM, Li QX, Collins S, Savage G, Laws S, et al. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. The journal of prevention of Alzheimer’s disease. 2019;6(4):248-55. 45. Jack CR, Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without DementiaAmyloid, Tau, and Neurodegeneration Biomarker Profiles and Memory Decline In Individuals Without DementiaAmyloid, Tau, and Neurodegeneration Biomarker Profiles and Memory Decline In Individuals Without Dementia. Jama. 2019;321(23):2316-25. 46. Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology. 2019;92(14):e1567-e79. 47. Grøntvedt GR, Lauridsen C, Berge G, White LR, Salvesen Ø, Bråthen G, et al. The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up. Journal of Alzheimer’s disease : JAD. 2020;74(3):829-37. 48. Teitsdottir UD, Jonsdottir MK, Lund SH, Darreh-Shori T, Snaedal J, Petersen PH. Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions. Alzheimers Res Ther. 2020;12(1):92. 49. de Wolf F, Ghanbari M, Licher S, McRae-McKee K, Gras L, Weverling GJ, et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain : a journal of neurology. 2020;143(4):1220-32. 50. Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, et al. Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):e252-e60. 4
RkJQdWJsaXNoZXIy MjY0ODMw